

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**ESPS manuscript NO:** 20838

**Title:** Hepatitis C virus: A time for decisions. Who should be treated and when?

**Reviewer's code:** 00069693

**Reviewer's country:** Brazil

**Science editor:** Xue-Mei Gong

**Date sent for review:** 2015-06-24 10:56

**Date reviewed:** 2015-07-02 22:27

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[ Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

General considerations It is well written article about current and relevant theme. The authors conducted a review of HCV infection and treatment strategies to reduce HCV-related morbidity and mortality by the different types of antiviral therapies. Specific considerations Abstract: I suggest that completion of the abstract need to be more specific and representative of the conclusions contained in the article text. Text: on the 2nd line of the 3rd paragraph of page 6, it would be desirable for the authors to give more current data (if any) of the related mortality with hepatitis C. It would also be attractive to the authors could explain or speculate why that "...anti-HCV seropositive Individuals with detectable serum HCV RNA have an increased risk of dying from all causes, whereas the risk for anti-HCV seropositives with negative HCV RNA is similar of seronegative HCV Individuals. The realization that "...individuals with chronic hepatitis C having an active infection manifested by HCV-RNA positivity should not benefit from antiviral treatment to reduce both their overall mortality as well as hepatic disease mortality risk. "(Page 7, last sentence) and that "... rather early than later therapy of HCV infected individuals would be even more efficacious than waiting particularly if it includes all cases from F0-F4 hepatic disease."(1st paragraph, page 11), I believe that



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

these information deserve highlight the conclusions, as they are important information for the readers. The same applies to the claim that "...that treatment regimens without any restrictions would result in a substantial reduction in health care costs and simultaneously reduce the number of infected Individuals who are infected can infect others." (8st line, page 11). In the 1st line of the 3rd paragraph of page 10, the reference to authors should follow "et al." instead of being placed at the end of the sentence. In 2nd line of page 13, I think there is missed a word after "... is much more (what?) Than an hepatic disease ... "

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**ESPS manuscript NO:** 20838

**Title:** Hepatitis C virus: A time for decisions. Who should be treated and when?

**Reviewer's code:** 02942902

**Reviewer's country:** Japan

**Science editor:** Xue-Mei Gong

**Date sent for review:** 2015-06-24 10:56

**Date reviewed:** 2015-06-29 12:25

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

## COMMENTS TO AUTHORS

This paper is an important review article. The format should be changed in accordance with the journal's instructions. In addition, minor errors should be revised. \*Page 9: In contrast, the newly developed direct acting (DNA) → DAA? \*Page 11: ...more convenient to administor (→ administer?) and were associated (→ associated?) with fewer side effects \* 'IFN-based therapies' and 'IFN based therapies' were used in the text. Please unify the style. \*Abbreviation should be defined in the abstract and on first mention in the text. There are other trifling errors. Please carefully revise the manuscript.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**ESPS manuscript NO:** 20838

**Title:** Hepatitis C virus: A time for decisions. Who should be treated and when?

**Reviewer's code:** 00071640

**Reviewer's country:** Turkey

**Science editor:** Xue-Mei Gong

**Date sent for review:** 2015-06-24 10:56

**Date reviewed:** 2015-06-29 20:14

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[ Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[ Y] No	

## COMMENTS TO AUTHORS

Dear author, This manuscript is informative and well written.